Catalent
Catalent is a global CDMO supporting GS010/LUMEVOQ® manufacturing, including process transfer and the operational readiness needed to reliably supply clinical and regulatory programs.
Manufacturing and CMC Partner
Catalent is a global CDMO supporting GS010/LUMEVOQ® manufacturing, including process transfer and the operational readiness needed to reliably supply clinical and regulatory programs.
Clinical and Hospital Network
CHNO des Quinze-Vingts is a leading ophthalmology hospital that has played a crucial role in patient access and treatment delivery for GS010, helping translate GenSight Biologics’ gene therapy into real-world clinical care.
Scientific and Research Collaborators
Institut de la Vision is a world-class center for vision science and a natural partner for GenSight Biologics, contributing deep ophthalmology expertise that supports work across retinal disease and vision restoration.
The Friedrich Miescher Institute is a high-caliber research institute collaborating on scientific work relevant to GenSight Biologics’ pipeline and the evolution of its technology platforms.
Technology and IP Licensing Partners
Inserm Transfert provides access to key intellectual property underpinning GS010, helping secure the rights needed to advance development and, ultimately, commercialization.
President and Fellows of Harvard College is the licensor associated with the Harvard Master Cell Bank used in connection with GS010, supporting critical foundations for development and manufacturing.
AFM-Téléthon contributes through a scientific-data licensing framework that strengthens the knowledge base supporting GS010 development.
UPMC participates in the same scientific-data licensing framework, supporting GS010 related development work through access to relevant data assets.
MIT licenses patent rights relevant to GS030, supporting GenSight Biologics’ optogenetics platform and its ambition to restore vision through novel mechanisms.
The University of Alberta is a co-holder of patent rights referenced in the GS030 context, complementing the MIT licensing framework that supports the platform’s scientific foundations.
Adverum Biotechnologies provides a non-exclusive patent license referenced for GS030, supporting GenSight Biologics’ ability to operate and develop within the optogenetics landscape.
Consortium and Program Partners
The Sight Again Program is a collaborative framework designed to accelerate vision restoration innovations by aligning complementary technologies, partners and resources around a shared objective.
Bpifrance, through the Investment for the Future (PIA) program, is a public funding partner supporting the structure and momentum of Sight Again, helping turn ambitious R&D into executable development plans.
The Website uses cookies. Alongside the cookies that are strictly necessary for its operation, we would like to use cookies to (1) remember your video-playback preferences, (2) measure the Website's traffic and usage, and (3) support advertising measurement and conversion tracking, as described in our Cookie Policy. By clicking "Accept all," you consent to the use of all these cookies. By clicking "Reject all," you decline every cookie other than those that are strictly necessary. You can change your choices at any time by clicking "Cookies management."